Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Avidity Biosciences (NASDAQ:RNA) and maintained a $35 price target on the stock.

March 04, 2024 | 6:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterated a Buy rating on Avidity Biosciences and maintained a $35 price target.
Analyst ratings, especially from reputable firms like Needham, can significantly influence investor sentiment and stock prices. A reiterated Buy rating and a maintained price target suggest confidence in the company's future performance, potentially leading to positive short-term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100